Compare ACLS & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACLS | BLLN |
|---|---|---|
| Founded | 1995 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.6B |
| IPO Year | 2000 | 2025 |
| Metric | ACLS | BLLN |
|---|---|---|
| Price | $144.11 | $93.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $101.50 | ★ $126.71 |
| AVG Volume (30 Days) | 374.2K | ★ 795.0K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 103.40 |
| EPS | ★ 1.05 | 0.48 |
| Revenue | ★ $839,048,000.00 | $305,112,000.00 |
| Revenue This Year | $1.93 | $46.29 |
| Revenue Next Year | $7.91 | $30.14 |
| P/E Ratio | ★ $133.48 | $194.44 |
| Revenue Growth | N/A | ★ 99.97 |
| 52 Week Low | $73.60 | $61.96 |
| 52 Week High | $193.78 | $150.44 |
| Indicator | ACLS | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 53.58 | 37.20 |
| Support Level | $141.55 | $73.46 |
| Resistance Level | $148.97 | $99.29 |
| Average True Range (ATR) | 7.53 | 6.90 |
| MACD | 2.31 | -4.42 |
| Stochastic Oscillator | 96.61 | 11.29 |
Axcelis Technologies Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. Geographically, the group has a business presence in North America, Asia Pacific, and Europe, of which key revenue is derived from the Asia Pacific.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.